Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Breast Neoplasms 5Brain Neoplasms 5Glioblastoma 3Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1

Interventions

Pemetrexed 20Bevacizumab 10Radiotherapy 8Spinal Puncture 7osimertinib 6Methotrexate 6Magnetic Resonance Spectroscopy 6aflutinib 5Topotecan 5Specimen Handling 5Trastuzumab 4Temozolomide 4Radiotherapy, Intensity-Modulated 4Dexamethasone 3trastuzumab deruxtecan 2pembrolizumab 2paclitaxel-Angiopep-2 conjugate 2omburtamab I-131 2merphos 2lorlatinib 2aumolertinib 2WP 744 2Vitamin B 12 2Rituximab 2Radiation 2Folic Acid 2Drug Therapy 2Cytarabine 2Cyclophosphamide 2Capecitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Carcinomatosis × sacituzumab govitecan × CNS × Clear all
NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

Guangzhou Medical University

Phase 1/2 Recruiting
34 enrolled
BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡